WebApr 20, 2024 · PRIMARY OBJECTIVES: I. To estimate the maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D) of tegavivint administered as an … WebTegatrabetan (BC-2059) C28H36N4O6S2 CID 91193182 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological ...
Tegatrabetan – Bioquote
WebTegatrabetan. Catalog No. T5642 CAS 1227637-23-1. Synonyms: BC2059. BC2059 is a small molecule inhibitor of the Wnt/beta-catenin pathway with potential antineoplastic … WebTegatrabetan. Tegatrabetan (BC2059) is a β-Catenin antagonist. Tegatrabetan disrupts the binding of β-catenin with the scaffold protein transducin β-like 1 (TBL1). CWP232228. CWP232228, a highly potent selective Wnt/β-catenin signaling inhibitor, antagonizes binding of β-catenin to T-cell factor (TCF) in the nucleus. sae and metric thread gauge
Tegavivint C28H36N4O6S2 - PubChem
WebNational Center for Biotechnology Information. 8600 Rockville Pike, Bethesda, MD, 20894 USA. Contact. Policies. FOIA. HHS Vulnerability Disclosure. National Library of … WebTegatrabetan –TREATED CELL Transcription Turned “OFF” 4 Tegatrabetan Binds in Pocket 1 Kicks Out Beta Catenin, SMRT and NCOR Re-attach 2 ‘Free’ Beta Catenin … WebMar 3, 2024 · This phase Ib trial is to find out the best dose, possible benefits and/or side effects of osimertinib and tegavivint as first-line therapy in treating patients with EGFR-mutant non-small cell lung cancer that has spread to other places in the body (metastatic). isf area